• yl23455永利官网

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR-TRC-12002072】Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

    基本信息
    登记号

    ChiCTR-TRC-12002072

    试验状态

    正在进行

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2012-04-04

    临床申请受理号

    /

    靶点

    /

    适应症

    women undergoing IVF-ET cycles

    试验通俗题目

    Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

    试验专业题目

    Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    The effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

    试验分类
    试验类型

    随机平行对照

    试验分期

    其它

    随机化

    RCT

    盲法

    Double-blind

    试验项目经费来源

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong

    试验范围

    /

    目标入组人数

    60

    实际入组人数

    /

    第一例入组时间

    1990-01-01

    试验终止时间

    1990-01-01

    是否属于一致性

    /

    入选标准

    1. History of 2 episodes of poor ovarian response (less than 3 mature follicles on ovulatory dose of hCG or less than 3 mature oocytes retrieved) despite maximal stimulation; or 2. Patients fulfill two out of three of the following features: I.Age >=40 or any other risk factors: (1)History of ovarian surgery; (2)History of salpingectomy; (3)History of chemotherapy; (4)Present of ovarian endometrioma.；

    排除标准

    1. Body mass index more than 30kg/m2; 2. Absent of one ovary; 3. History of polycystic ovarian disease; 4. Present of uterine abnormalities; 5. Present of endocrine/metabolic/autoimmune disease; 6. Incompetence or refuse for informed consent.；

    研究者信息
    研究负责人姓名
    试验机构

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    Prince of Wales Hospital的其他临床试验

    更多

    最新临床资讯

    yl23455永利官网企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品